Insider Selling: Opus Genetics (NASDAQ:IRD) CFO Sells $127,120.00 in Stock

Opus Genetics, Inc. (NASDAQ:IRD) CFO Robert Gagnon sold 28,000 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $4.54, for a total transaction of $127,120.00. Following the completion of the sale, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at $2,525,942.50. The trade was a 4.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Opus Genetics Stock Performance

Shares of Opus Genetics stock opened at $6.07 on Friday. Opus Genetics, Inc. has a 1 year low of $1.32 and a 1 year high of $7.07. The firm’s 50-day simple moving average is $3.86 and its 200-day simple moving average is $4.32. The firm has a market cap of $501.69 million, a PE ratio of -4.50 and a beta of 0.58.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $2.63 million. On average, equities analysts predict that Opus Genetics, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analyst Weigh In

IRD has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Opus Genetics in a research report on Wednesday. TD Cowen began coverage on shares of Opus Genetics in a research note on Wednesday, July 29th. They set a “buy” rating for the company. BTIG Research reissued a “buy” rating and set a $12.00 target price on shares of Opus Genetics in a report on Wednesday. Leerink Partners started coverage on shares of Opus Genetics in a research report on Thursday, May 21st. They issued an “outperform” rating and a $10.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Opus Genetics presently has a consensus rating of “Moderate Buy” and an average target price of $11.92.

Institutional Investors Weigh In On Opus Genetics

Several large investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC boosted its holdings in shares of Opus Genetics by 42.9% during the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after acquiring an additional 1,435,407 shares during the period. BlackRock Inc. acquired a new stake in shares of Opus Genetics in the 2nd quarter worth about $12,809,000. Trails Edge Capital Partners LP acquired a new stake in shares of Opus Genetics in the 2nd quarter worth about $11,276,434. Balyasny Asset Management L.P. bought a new stake in Opus Genetics in the 4th quarter valued at about $5,463,000. Finally, Millennium Management LLC bought a new stake in Opus Genetics in the 4th quarter valued at about $4,025,000. 14.97% of the stock is owned by institutional investors and hedge funds.

More Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Encouraging gene-therapy results: Opus reported positive three- and six-month results from the low-dose cohort of its Phase 1/2 OPGx-BEST1 trial for inherited retinal disease. All five participants showed clinically meaningful visual-function improvement, while no serious adverse events or dose-limiting toxicities were observed. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: Path toward pivotal testing: Following an FDA Type C meeting, regulators aligned with a potential pivotal endpoint involving retinal sensitivity and patient-reported outcomes. Opus expects to complete second-cohort dosing in the fourth quarter of 2026 and potentially begin Phase 3 dosing in 2027. Management also said its cash runway extends into 2029, reducing near-term financing risk. Opus Genetics Reports Positive OPGx-BEST1 Data
• Positive Sentiment: Analyst support increased: Wedbush raised its price target to $13 from $10 and maintained an “outperform” rating. Oppenheimer raised its target to $20 from $10, while BTIG, Chardan Capital and HC Wainwright reaffirmed bullish ratings with targets ranging from $8 to $13. These targets imply substantial potential upside, although they remain dependent on clinical execution.
• Positive Sentiment: Options activity signals optimism: Traders purchased 4,820 call options, approximately 681% above typical volume, suggesting increased speculative interest in further gains.
• Neutral Sentiment: Analyst views are not unanimous: Coverage remains broadly bullish, but some analysts hold more cautious ratings, making the overall outlook supportive but mixed. Analysts’ Opinions Are Mixed on Opus Genetics
• Negative Sentiment: Insider sale: CFO Robert Gagnon sold 28,000 shares worth about $127,120 to cover tax withholding tied to equity vesting. The transaction was relatively small and attributed to taxes, but could still be viewed as a modest negative signal.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.